Although the overexpression of PrPC in cancer cells results in therapy-resistance, researchers have taken advantage of this characteristic to synthesize PrPC-Apt-functionalized doxorubicin-oligomer-AuNPs (PrPC-AptDOa) which could target PrPC-overexpressed CRC (83). The gene discussed is PRNP; the disease is colorectal carcinoma.